Peptides effective in the treatment of conditions requiring the removal or destruction of cells
The embodiments are directed to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides.
1. A synthetic peptide consisting of the peptide selected from (i) Ile-Asp-Leu-Leu-Gln-Gly-Arg-Thr-Arg-Asn-Arg-Cys (SEQ ID NO. 1); or (ii) Phe-His-Asp-Leu-Lys-Lys-His-Cys-Ile-Lys (SEQ ID NO. 2) or salts thereof.
2. The synthetic peptide of claim 1 , wherein the peptide is Ile-Asp-Leu-Leu-Gln-Gly-Arg-Thr-Arg-Asn-Arg-Cys (SEQ ID NO. 1).
3. The synthetic peptide of claim 1 , wherein the peptide is Phe-His-Asp-Leu-Lys-Lys-His-Cys-Ile-Lys (SEQ ID NO. 2).
4. A composition comprising the peptide of claim 1 , and a carrier therefor.
5. A synthetic peptide of SEQ ID NO: 1 or SEQ ID NO: 2 with up to 25 additional amino acids flanking either the amino or carboxy end of the peptide, wherein the peptide is cytotoxic.
6. The peptide of claim 5 , wherein the peptide is Ile-Asp-Leu-Leu-Gln-Gly-Arg-Thr-Arg-Asn-Arg-Cys (SEQ ID NO. 1).
7. The peptide of claim 5 , wherein the peptide is Phe-His-Asp-Leu-Lys-Lys-His-Cys-Ile-Lys (SEQ ID NO. 2).
8. A composition comprising the peptide of claim 5 , and a carrier therefor.
9. A method of treating a benign or malignant tumor in a mammal comprising locally administering to the mammal in need thereof a therapeutically effective amount of the peptide consisting of the sequence selected from: (i) Ile-Asp-Leu-Leu-Gln-Gly-Arg-Thr-Arg-Asn-Arg-Cys (SEQ ID NO. 1); or (ii) Phe-His-Asp-Leu-Lys-Lys-His-Cys-Ile-Lys (SEQ ID NO. 2).
10. The method of claim 9 , wherein the method is carried out on the mammal before, during, or after treatment of the mammal with a treatment selected from the group consisting of surgical excision, transplantation, grafting, chemotherapy, immunotherapy, vaccination, thermal or electrical ablation, cryotherapy, laser therapy, phototherapy, gene therapy, and radiation.
11. The method of claim 9 , wherein the tumor is a benign or malignant tumor of a tissue selected from the group consisting of lung, breast, stomach, pancreas, prostate, bladder, bone, ovary, skin, kidney, sinus, colon, intestine, stomach, rectum, esophagus; heart, spleen, salivary gland, brain and its coverings, spinal cord and its coverings, muscle, connective tissue, adrenal, parathyroid, thyroid, uterus, testis, pituitary, reproductive organs, liver, gall bladder, eye, ear, nose, throat, tonsils, mouth, and lymph nodes and lymphoid system.
12. The method of claim 9 , where the tumor is a hyperplasia of a tissue selected from the group consisting of lung, breast, stomach, pancreas, prostate, bladder, bone, ovary, skin, kidney, sinus, colon, intestine, stomach, rectum, esophagus, heart, spleen, salivary gland, brain and its coverings, spinal cord and its coverings, muscle, connective tissue, adrenal, parathyroid, thyroid, uterus, testis, pituitary, reproductive organs, liver, gall bladder, eye, ear, nose, throat, tonsils, mouth, and lymph nodes and lymphoid system.
13. The method of claim 9 , wherein said tumor is prostatic hyperplasia.